Alterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathway

Alterity Therapeutics Ltd (ASX:ATH) has received official US Food and Drug Administration meeting minutes confirming a ...
clinicaladvisor.com

Multiple System Atrophy: A Common Form of Atypical Parkinsonism

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Alterity kicks FDA goal as US regulator backs Phase III pathway for ATH434 in MSA

Official minutes from Alterity Therapeutics’ End-of-Phase II meeting with the US Food and Drug Administration, confirm a ...
Medical Xpress

Interferon-gamma drives brain pathology in a mouse model of multiple system atrophy

Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The resulting ...
Medscape

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulin

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.
Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Medical Xpress

Targeting brain iron in multiple system atrophy offers therapeutic potential

Researchers from the Florey Institute of Neuroscience and Mental Health have advanced understanding of the biological mechanisms underlying a rare neurological disease called Multiple System Atrophy ...
Science Daily

Researcher's technology differentiates between Parkinson's disease and multiple system atrophy

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease (PD) and multiple system atrophy (MSA). Scientists have found a way to distinguish ...
Nasdaq

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Monthly Prescribing Reference

Emrusolmin Fast Tracked for Multiple System Atrophy

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Nature

Pathophysiology and Mechanisms of Multiple System Atrophy

Multiple system atrophy (MSA) is a relentlessly progressive adult-onset synucleinopathy characterised by the intracytoplasmic accumulation of α-synuclein in oligodendrocytes, manifesting as glial ...